Oncology Companion Diagnostics (CDx)
The number of Oncology drugs that require a Companion Diagnostic test to select patients most likely to benefit from treatment is increasing. In addition to patient stratification, diagnostics are increasingly used also for prognostic and patient monitoring purposes. This raises a number of questions and challenges for the pharmaceutical, diagnostic and biotech industries.
- When and why should a pharmaceutical consider incorporating a Companion Diagnostic into the drug development process?
- What are the regulatory requirements and challenges in different markets?
- What types of assays and platforms are suitable for development into CDx?
- What type of partner should a pharmaceutical select for CDx development and delivery to the market?
Please see the videos below for discussion and insight into these questions, based on an interview of Dr Berwyn Clarke, Lab21 by Nathan Nagel, Oncology Pharma.